Points clés
- The Brazilian health authority Anvisa approved the drug ocrelizumab for young patients aged 12 and older.
- Marketed as Ocrevus, this treatment became the first high-efficacy treatment approved for adolescents in Brazil.
- By targeting B cells, the drug reduces nerve damage and inflammation caused by multiple sclerosis.
- To receive this treatment, patients must be 12 years old and weigh at least 40 kilograms.
En chiffres
The Brazilian National Health Surveillance Agency (Anvisa) has expanded the use of the drug ocrelizumab, authorizing its use for multiple sclerosis patients aged 12 and older. This treatment, which is administered for the relapsing-remitting type known as the most common form of the disease, stands out as a new hope for young patients.
Sold under the brand name Ocrevus by Roche Farma Brasil, the drug holds the distinction of being the first high-efficacy treatment approved for adolescent patients in Brazil. For the treatment to be administered, patients must be at least 12 years old and weigh 40 kilograms or more.
Ocrelizumab is a monoclonal antibody that targets B cells in the immune system, reducing the damage to the myelin sheath and inflammation in the brain. This selective mechanism of action significantly preserves the body's capacity to fight infections while slowing the progression of the disease.
Réagir à cet article
Poser une question
Réponses générées par IA, à partir de cette actualité uniquement.
Questions fréquentes
- What exactly is this newly approved multiple sclerosis treatment in Brazil?
- Ocrelizumab (Ocrevus) is a drug approved for relapsing-remitting multiple sclerosis patients aged 12 and older, which reduces the immune system's attack on neurons by targeting B cells.
- What are the physical requirements for young patients to use this drug?
- For the drug to be used, young patients must be at least 12 years old and their body weight must be 40 kilograms or over.
- How does this drug affect the course of multiple sclerosis?
- The drug targets the CD20 protein on B cells, temporarily deactivating these cells. Thus, it controls the inflammation that occurs in the disease and delays the further worsening of the disease.
Ceci est un court résumé généré par l'IA. L'article complet est à la source.
Lire l'article complet à la sourceveja.abril.com.brComment nous produisons notre contenu →